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Abstract 
A novel carbon-11 radiolabelling methodology for the synthesis of the dialkylcarbonate 
functional group has been developed. The method uses cyclotron-produced short-lived 
[11C]CO2 (half-life 20.4 min) directly from the cyclotron target in a one-pot synthesis. Alcohol 
in the presence of base trapped [11C]CO2 efficiently forming an [11C]alkylcarbonate 
intermediate that subsequently reacted with an alkylchloride producing the di-substituted 
[11C]carbonate (34% radiochemical yield, determined by radio-HPLC) in 5 minutes from the 
end of [11C]CO2 cyclotron delivery. 
Introduction 
Positron emission tomography (PET) is an imaging technique able to detect and monitor 
specific target proteins in vivo.[1] The use of PET imaging has advanced in the last few decades 
to become a valuable tool in clinical diagnostics, medical research and drug discovery.[2] PET 
relies on the use of tracer amounts of imaging probes (radiotracers). The administration of 
radiotracers allows biochemical process to be imaged and quantified in vivo without 
manifestation of pharmacological or toxicological effects.[3] 
Carbon-11 (11C) is one of the most common radionuclides used for the synthesis of PET 
radiotracers. The short half-life of 11C (20.4 min) makes it an attractive radionuclide as it 
enables the collection of a sufficient amount of PET data while keeping the subject radiation 
dose and exposure time to minimum. Furthermore it allows orthologus substitution with 
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carbon-12 in biologically active molecules with no alteration of the parent molecule’s physico-
chemical and pharmacological properties. Carbon-11 is commonly produced in the form of 
[11C]carbon dioxide ([11C]CO2).[4] [11C]CO2 is usually converted into more reactive secondary 
precursors such as [11C]methyl iodide ([11C]CH3I), [11C]carbon monoxide ([11C]CO), and 
[11C]phosgene ([11C]COCl2).[5] As these multistep conversion processes are time consuming, 
the use of [11C]CO2 for directly radiolabelling functional groups is highly attractive. 
[11C]CO2 is a weak electrophile with an affinity for electron-donating reagents such as amines 
and organometallics.[6] However, due to the thermodynamic and kinetic properties of 
[11C]CO2, it has high activation energy which requires the use of highly reactive reagents, 
temperatures, pressures, or the presence of a catalyst.[7] Nevertheless, the primary synthon, 
[11C]CO2, has been deployed successfully for the synthesis of 11C-compounds that contain 
carbonyl groups such as [11C]carbamates,[8] amide,[9] and [11C]ureas.[10] However, the 
radiolabelling of the carbonyl group of carbonates from [11C]CO2 has not yet been established. 
To date, the synthesis of [11C]carbonates has relied on the use of [11C]COCl2 which is produced 
from a multistep process starting from cyclotron-produced [11C]CH4, conversion to [11C]CCl4 
and then to [11C]COCl2.[11] Although this 11C-carbonate reaction is rapid and efficient, routine 
production of [11C]COCl2 requires a multistep syntheses and specialized equipment, thereby 
restricting its widespread use.[11] 
As the carbonate functional group is found in prodrug compounds as well as being an 
intermediate in organic synthesis [12] we aimed to develop a simple and robust radiolabelling 
methodology that uses [11C]CO2 for the synthesis of [11C]carbonates. Here we present a rapid, 
one-pot radiosynthetic strategy using [11C]CO2 directly from the cyclotron, avoiding the need 
for specialized equipment and multistep syntheses. 
Materials and Methods 
All purchased chemicals were used without further purification. Chemicals were purchased in 
highest available purity from Sigma-Aldrich and Alfa Aesar and used as received (> 99 % 
purity). All solvents were purchased as anhydrous in highest available purity (> 99.8 % purity) 
from Sigma-Aldrich. 
 
[11C]CO2 was produced by a Siemens RDS112 cyclotron (St Thomas’ Hospital, London, 
United Kingdom) via the 14N(p,α)11C nuclear reaction. Typical irradiation times for exploratory 
work was 1 minute,10 µA, bombardment typically yielding ca. 300 MBq [11C]CO2 at end of 
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cyclotron bombardment. Radiolabelling reactions were performed in a 1.5 mL screw top vial 
with a “V” internal shape. HPLC analysis was performed on an Agilent 2060 Infinity HPLC 
system with a variable wavelength detector (254 nm was used as default wavelength). An 
Agilent Eclipse XDB-C18 reverse-phase column (4.6 x 150 mm, 5 µm) was used at a flow rate 
of 1 mL/min and H2O/MeOH (HPLC grade solvents with 0.1 % TFA) gradient elution (flow 
rate: 1 mL/min, 0-2 min: 5 % MeOH, 2-11 min: 5 to 95 % MeOH linear gradient, 11-13 min: 
90 % MeOH, 13-14 min: 90 % to 5 % MeOH linear gradient, and 14-15 min: 5 % MeOH). The 
RCY was estimated by radio-HPLC and defined as the area under the 11C-product peak 
expressed as a percentage of the total 11C labelled peak areas observed in the chromatogram. 
Molar radioactivity was calculated from analytical HPLC sample of 25 μL. A calibration curve 
of known mass quantity versus HPLC peak area (254 nm) was used to calculate the mass 
concentration of the 25 μL radiolabelled compound. The identity of the radiolabelled 
compound peak was confirmed by HPLC co-injection of a nonradioactive reference compound 
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Figure 1. Method by Salvatore et al. [7] for the synthesis of carbonates using non-radioactive CO2. 
 
As a starting point we selected the method developed by Salvatore et al. [7] (Figure 1) for the 
synthesis of carbonates. The established method used non-radioactive CO2, an alcohol 
derivative and benzylchloride (BzCl) in the presence of Cs2CO3, TBAI in DMF to produce the 
corresponding carbonate derivative efficiently. By substituting CO2, with [11C]CO2 and 





































Table 1 Optimisation of [11C]1 synthesis.  






Entry[a] Base Trapping 
efficiency (%) 
Temperature (oC) Solvent RCY (%)[b] 
1 Cs2CO3 95.2 25 DMF 24 
2 Cs2SO4 1.5 25 DMF 0 
3 CsI 4.3 25 DMF 5 
4 CsF 33.5 25 DMF 0 
6 K2CO3 10 25 DMF 0 
7 CaCO3 0 25 DMF 0 
8 Cs2CO3 20 25 CH3CN 0 
9 Cs2CO3 65 25 DMSO 0 
10 Cs2CO3 >95% 65 DMF 33 
11[c] Cs2CO3 >95% 100 DMF 82, 74 
[a] Reaction conditions: Isopropanol (22 µmol), Cs2CO3 (66 µmol), TBAI (66 µmol) and 
organohalide (66 µmol) in 500 µL DMF, 10 mins from end of delivery (EOD) (n=1). [b] 
The non-isolated radiochemical yield determined by radio-HPLC analysis of the crude 
product. [c] n=2 
 
[11C]CO2 was trapped in isopropyl alcohol in the presence of Cs2CO3, forming an 
[11C]isopropylcarbonate intermediate that subsequently reacted with BzCl to produce 
[11C]benzyl isopropyl carbonate ([11C]1) in a moderate radiochemical yield (RCY)[13] of 24% 
(Table 1, entry 1). Interestingly, almost all the cyclotron-produced [11C]CO2 was trapped 
within the reaction mixture at room temperature (> 95%); any unreacted radioactive [11C]CO2 
was immobilized on an ascarite trap connected to the vial vent needle.[14] 
* 
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In an attempt to increase the RCY, Cs2CO3 was replaced with Cs2SO4 (Table 1, entry 2). The 
trapping efficiency of [11C]CO2 dropped significantly from 95.2% to 1.5%. Since Cs2CO3 
contributed towards the trapping of [11C]CO2 efficiently, we investigated whether the Cs+ or 
the CO32- ion was responsible for the high [11C]CO2 trapping efficiency. Of a number of 
caesium bases explored (Table 1, entries 3-5), CsI and CsF trapped only minute amounts of 
[11C]CO2 (4% and 34%, respectively), indicating that the basicity of the reaction mixture had 
a major effect on trapping efficiency. These results can be explained by the ability of a strong 
base to deprotonate the alcohol present in the reaction mixture enabling it to react with 
[11C]CO2 to form a 11C radiolabelled intermediate. The importance of CO32- was then explored 
by comparing Cs2CO3 with other carbonate bases (K2CO3 and CaCO3, Table 1, entries 6 and 
7). The trapping efficiencies were extremely low for both reagents. High trapping in the 
reaction mixture with Cs2CO3 is therefore most likely due to its superior solubility in organic 
solvents.  
 
Table 2 Optimisation of [11C]1 synthesis using alternative bases. 
Entry[a] Base (eq) TBAI (eq) Temp (oC) RCY (%)[b]  
1[c] DBU (3) 3 100 6  
2 c DBU (3) - 100 0  
3 NaH (1) 1 100 26  
4[d] NaH (1) 1 60 31±2  
5 c NaH (0.5) 1 60 18  
6 NaH (2) 1 60 0  
7c NaH (0.5) - 60 6  
8 NaH (1) 3 60 7  
 [a] Isopropanol (1 equiv., 22 µmol), BzCl (3 equiv.), TBAI (1-3 equiv.) 
and base (1-3 equiv.) in 500 L DMF reaction time 5 mins from EOD. 
[b] The non-isolated radiochemical yield determined by radio-HPLC 
analysis of the crude product. [c] Reaction time of 10 mins from EOD. 
[d] n=3 




In a further attempt to increase the RCY of [11C]1, a number of aprotic solvents were screened 
(CH3CN and DMSO, Table 1, entries 8 and 9). However, these solvents did not produce [11C]1 
and the trapping efficiency was poor (20% and 65%, respectively). Reaction dependency on 
temperature was subsequently examined. The RCY of [11C]1 improved from 24% to 33% by 
increasing the reaction temperature from 25 oC to 65 oC (Table 1, entry 10). Increasing the 
temperature to 100 oC promoted the product formation and resulted in the highest observed 
RCY (82%, Table 1, entry 11). This might be rationalised by an increase in Cs2CO3 solubility 
at higher temperatures. However, due the presence of Cs2CO3 as a reagent, low molar activities 
(Am) were observed. The low Am (2 GBq/μmol in this case) is likely due to release of non-
radioactive CO2 from Cs2CO3. CO32- deprotonates the alcohol to form HCO3-, which at high 
temperature has the potential to decompose releasing non-radioactive CO2 causing isotopic 
dilution and low Am of the [11C]CO2. We therefore focused on improving Am by substituting 
Cs2CO3 with an alternative base.  
1,8-diazabicyclo[5.4.0]undecene (DBU) is a basic amine that has been shown to 
retain [11C]CO2 in organic solutions.[9] Replacing Cs2CO3 with DBU (Table 2, entry 1) 
resulted in [11C]1 formation, but with low RCY (6%). The low RCY could be due to DBU 
being unable to deprotonate isopropyl alcohol efficiently. We opted for a stronger base, NaH, 
which was able to deprotonate the isopropyl alcohol. Using a ratio of 1:1 NaH:isopropanol 
(equiv.) at 100 oC, [11C]1 was obtained with a RCY of 26% (Table 2, entry 3). Decreasing the 
temperature from 100 oC to 60 oC slightly improved the RCY (31%, Table 2, entry 4).[15] 
Decreasing the ratio of NaH:isopropanol (from 1:1 to 0.5:1) reduced the RCY further to 18% 
(Table 2, entries 5). Increasing the ratio NaH:isopropanol 2:1 did not produce the target product 
(Table 2, entry 6). Increasing the amount of TBAI to 3 equiv. or removing it completely also 
did not improve the RCY (Table 2, entries 7 and 8). 
Conclusions 
In conclusion, we have developed a radiolabelling methodology for the synthesis of 
[11C]carbonates using [11C]CO2 directly from the cyclotron. The carbonate [11C]1 was 
synthesized by bubbling [11C]CO2 into a solution containing alkylchloride, alcohol and a base 
in DMF. The choice of the base was critical for maximising the RCY and Am. The first protocol 
uses Cs2CO3 and produces the target 11C radiolabelled product in a high RCY and low Am. The 
second strategy, which uses NaH, produced [11C]1 in high Am and moderate RCY. These 
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methodologies are a simple and practical alternative to 11C-phosgene for the synthesis of 11C-
carbonates. 11C-phosgene synthesis is technically challenging to implement and requires the 
use of specialist equipment. The developed strategies described here use readily available 
labware and converts [11C]CO2 directly to [11C]carbonates in rapid synthesis times.  
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used to produce higher amounts of radioactivity (typically 60 GBq). It is therefore estimated that this 
would increase the Am to > 50 GBq/µmol at end of synthesis. 
 
